Literature DB >> 28049641

Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis.

Leslie Skeith1, Marc Carrier1,2, Susan E Robinson3, Samah Alimam3, Marc A Rodger1,2,4.   

Abstract

We performed a meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with essential thrombocythemia. Twenty-one trials and 756 pregnancies met inclusion criteria. The absolute VTE risk in the antepartum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clearly indicated or below a threshold where LMWH should be withheld (2.5%; 95% CI, 1.3-4.3). Postpartum, the absolute VTE risk is above a threshold where postpartum LMWH prophylaxis should be considered (4.4%; 95% CI, 1.2-9.5).
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28049641     DOI: 10.1182/blood-2016-09-728006

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Pregnancy and Pulmonary Embolism.

Authors:  Christopher Deeb Dado; Andrew Tobias Levinson; Ghada Bourjeily
Journal:  Clin Chest Med       Date:  2018-09       Impact factor: 2.878

Review 4.  Treatment options and pregnancy management for patients with PV and ET.

Authors:  Yoko Edahiro
Journal:  Int J Hematol       Date:  2022-04-08       Impact factor: 2.490

5.  Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety.

Authors:  Lukas Schrickel; Florian H Heidel; Parvis Sadjadian; Tatjana Becker; Vera Kolatzki; Andreas Hochhaus; Martin Griesshammer; Kai Wille
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-02       Impact factor: 4.553

Review 6.  Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.

Authors:  Joan How; Gabriela Hobbs
Journal:  Cancers (Basel)       Date:  2020-07-18       Impact factor: 6.639

Review 7.  A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

Authors:  Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison
Journal:  Br J Haematol       Date:  2018-11-13       Impact factor: 6.998

8.  Epidemiology of venous thromboembolism in Africa: a systematic review and meta-analysis protocol.

Authors:  Celestin Danwang; Mazou N Temgoua; Valirie Ndip Agbor; Aurel T Tankeu; Jean Jacques Noubiap
Journal:  BMJ Open       Date:  2017-10-10       Impact factor: 2.692

9.  Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.

Authors:  Dawn Maze; Sajida Kazi; Vikas Gupta; Ann Kinga Malinowski; Rouhi Fazelzad; Prakesh S Shah; Nadine Shehata
Journal:  JAMA Netw Open       Date:  2019-10-02

Review 10.  The 2020 revision of the guidelines for the management of myeloproliferative neoplasms.

Authors:  Sung-Yong Kim; Sung Hwa Bae; Soo-Mee Bang; Ki-Seong Eom; Junshik Hong; Seongsoo Jang; Chul Won Jung; Hee-Jin Kim; Ho Young Kim; Min Kyoung Kim; Soo-Jeong Kim; Yeung-Chul Mun; Seung-Hyun Nam; Jinny Park; Jong-Ho Won; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2020-12-04       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.